News

Clinical Trials Arena2h
Nuvig Therapeutics begins dosing in trial of NVG-2089 for CIDP
Nuvig Therapeutics has dosed the first subject in its Phase II INVGOR trial of NVG-2089 for individuals with CIDP.
Clinical Trials Arena20h
Childhood trauma and depressive predominance polarity in bipolar disorder
People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...
Clinical Trials Arena21h
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug
BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...